stock ticker hero image

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
April 20, 2024 3:00 pm ET
Delayed at least 20 minutes

View stock information

Latest news, events & financials

View all

Our pipeline shows our relentless pursuit of the next breakthrough.

Phase II programs
80+
Phase III programs
30+
Under review
10+
Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Girl getting blood pressure checked by health care professional

Sustainability

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our Impact Report 2022/2023

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories
Innovation

Our Q2 2023 earnings report

Merck’s (NYSE: MRK) Q2 2023 results reflect sustained underlying growth. Our company announced Q2 worldwide sales of $15.0 billion, an increase of 3% from Q2 2022. “We continue to make great progress as we advance our broad and deep pipeline, raise the bar of innovation, and bring forward leading-edge science to save and improve lives […]

Read more

Next: Our Q2 2023 earnings report

Innovation

Celebrating the opening of our latest state-of-the-art facility

The FLEx Center will help us continue to harness the power of leading-edge science with agility

Read more

Next: Celebrating the opening of our latest state-of-the-art facility

Innovation

Why we’re expanding and investing in our research and discovery efforts

Our commitment to innovation helps ensure a brighter future for patients everywhere

Read more

Next: Why we’re expanding and investing in our research and discovery efforts

Innovation

Our Q2 2023 earnings report

Merck’s (NYSE: MRK) Q2 2023 results reflect sustained underlying growth. Our company announced Q2 worldwide sales of $15.0 billion, an increase of 3% from Q2 2022. “We continue to make great progress as we advance our broad and deep pipeline, raise the bar of innovation, and bring forward leading-edge science to save and improve lives […]

Read more

Next: Our Q2 2023 earnings report

Innovation

Celebrating the opening of our latest state-of-the-art facility

The FLEx Center will help us continue to harness the power of leading-edge science with agility

Read more

Next: Celebrating the opening of our latest state-of-the-art facility

Innovation

Why we’re expanding and investing in our research and discovery efforts

Our commitment to innovation helps ensure a brighter future for patients everywhere

Read more

Next: Why we’re expanding and investing in our research and discovery efforts

Previous
Next

Unsubscribe from email alerts

Contact us banner image
For questions, please contact our team.

Contact investor relations